{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:16:21Z","timestamp":1785820581378,"version":"3.56.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be elucidated. We herein report the case of a 75-year-old man with peritoneal mesothelioma treated with cisplatin plus pemetrexed and subsequent nivolumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 75-year-old man was referred to our hospital due to lower abdominal pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Positron emission tomography-computed tomography (CT) showed the accumulation of fluorodeoxyglucose in an intraperitoneal mass. A histological examination of a laparoscopic biopsy specimen revealed malignant peritoneal mesothelioma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After 4 cycles of cisplatin plus pemetrexed and 13 subsequent cycles of pemetrexed maintenance therapy showed beneficial responses until CT revealed liver metastasis. Nivolumab was then administered as the second-line therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 3 cycles of biweekly nivolumab administration, he developed severe abdominal distention. CT revealed an intraperitoneal mass growing much more rapidly than ever, indicating hyperprogressive disease after nivolumab treatment. He ultimately died 51 days after the initial nivolumab administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>To our knowledge, this is the first report of hyperprogressive disease in a case of peritoneal mesothelioma after nivolumab treatment. While immune checkpoint inhibitors may be promising therapeutic strategies for treating malignant peritoneal mesothelioma, careful monitoring must be practiced with their application.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019956","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:24:53Z","timestamp":1590693893000},"page":"e19956","source":"Crossref","is-referenced-by-count":8,"title":["Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-2841","authenticated-orcid":false,"given":"Hiroaki","family":"Ikushima","sequence":"first","affiliation":[{"name":"Division of Respirology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Sakatani","sequence":"additional","affiliation":[{"name":"Division of Respirology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Ohara","sequence":"additional","affiliation":[{"name":"Division of Respirology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Division of Respirology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Usui","sequence":"additional","affiliation":[{"name":"Division of Respirology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"R1-20240308","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: a review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R2-20240308","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann Transl Med"},{"key":"R3-20240308","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"R4-20240308","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"key":"R5-20240308","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R6-20240308","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R7-20240308","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"R8-20240308","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"key":"R9-20240308","first-page":"659","article-title":"Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"R10-20240308","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4240\/wjgs.v1.i1.38","article-title":"Malignant peritoneal mesothelioma","volume":"1","author":"Munkholm-Larsen","year":"2009","journal-title":"World J Gastrointest Surg"},{"key":"R11-20240308","doi-asserted-by":"crossref","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","article-title":"Update on the management of malignant peritoneal mesothelioma","volume":"7","author":"Sugarbaker","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R12-20240308","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma","volume":"32","author":"Campbell","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"R13-20240308","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-20240308","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20240308","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"R16-20240308","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:19:47Z","timestamp":1709929187000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019956"}},"subtitle":["Case report"],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":16,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019956","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]}}}